Back

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, ALCHEMIST Chemo-IO Study

Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: Alchemist Chemo-IO

  • Clinical Trial Information

    Trial Contact: Deronvil, France; De Leon, Ma Theresa

    Trial Phone: 321.841.3498 ; 321.841.8284

  • IRB No: C21.022.02

    Protocol Abbrev: Alchemist A081801

    Principal Investigator: Jennifer E. Tseng, MD

    Phase: Drug: Phase III

    Age Group: Adult

    Secondary Protocol No: A081801

    Treatment: Arm A: Platinum doublet (Cisplatin, Pemetrexed, Carboplatin, Gemcitabine) Arm B: Platinum doublet + MK-3475 (pmbrolizumab) Arm C: Platinum doublet + MK-3475 (pmbrolizumab)

    Therapies Involved: Medication

    ClinicalTrials.gov ID: NCT04267848

  • Objective

    To compare the DFS and OS (dual primary endpoints) between combination MK-3475 (pembrolizumab) plus standard of care (Arm C) vs. standard of care (Arm A) in patients with stage IB-IIIA non-small cell lung cancer.

  • Key Eligibility

    Previously registered to A151216